Literature DB >> 24196091

Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?

Kiril Kiryazov1, Mariyka Stefova, Violeta Iotova.   

Abstract

Topical ocular medications have been widely prescribed and successfully used in children for the management of different ophthalmic disorders. We present 2 infants admitted to our pediatric intensive care unit who developed altered state of consciousness, hypotonia, hypothermia, bradycardia, and apnea after instillation of ophthalmic drops. The second infant also had hypotension and broncho-obstruction. Few days before admission, both infants were diagnosed with congenital glaucoma, and topical antiglaucoma treatment was initiated. Ophthalmic drops with brimonidine and brinzolamide were prescribed to both patients, whereas the second infant also received topical timolol. After elimination of other possible causes, the diagnosis of intoxication with topical antiglaucoma medications was established. After discontinuation of eye drops and vigorous symptomatic treatment, both infants recovered without sequels. Topically applied ophthalmic drops may cause life-threatening systemic adverse effects in infants, such as central nervous system depression and cardiogenic shock. Moreover, these 2 patients illustrate the importance of careful evaluation of all topical medications and their consideration as possible causes of the derangements in critically ill infants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24196091     DOI: 10.1097/PEC.0b013e3182aa1384

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  5 in total

1.  Association of Central Nervous System Depression With Topical Brimonidine When Used for Hemostasis: A Serious Adverse Event.

Authors:  Devorah R Shagalov; Drew Taylor; Rachel Schleichert; Jonathan Weiss; Eduardo Weiss
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

2.  In vivo assessment of aqueous humor dynamics upon chronic ocular hypertension and hypotensive drug treatment using gadolinium-enhanced MRI.

Authors:  Leon C Ho; Ian P Conner; Chi-Wai Do; Seong-Gi Kim; Ed X Wu; Gadi Wollstein; Joel S Schuman; Kevin C Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-24       Impact factor: 4.799

Review 3.  Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.

Authors:  Nevio Cimolai
Journal:  Clin Med Res       Date:  2019-08-28

Review 4.  Pediatric Glaucoma: Pharmacotherapeutic Options.

Authors:  Monica Samant; Anagha Medsinge; Ken K Nischal
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

5.  A Single Drop in the Eye - Effects on the Whole Body?

Authors:  Anu Vaajanen; Heikki Vapaatalo
Journal:  Open Ophthalmol J       Date:  2017-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.